CoCrystal Pharma to Present at August 20th Virtual Investor Summit Microcap Event

Rhea-AI Summary

CoCrystal Pharma (NASDAQ:COCP), a clinical-stage biotechnology company focused on developing novel antiviral therapeutics, is set to present at the virtual Investor Summit Microcap Forum on August 20, 2024. The event, themed around 50 micro-cap companies with catalysts or strong market performance, offers a platform for CoCrystal's management to showcase their company overview at 9:00 a.m. ET.

The presentation will highlight CoCrystal's work in targeting the replication process of influenza viruses, coronaviruses, and noroviruses. Investors will have the opportunity to engage in live Q&A sessions and schedule one-on-one meetings with the management team throughout the day. This event provides a valuable opportunity for qualified investors to gain insights into CoCrystal's progress and potential in the antiviral therapeutics market.

NEW YORK, NY / ACCESSWIRE / August 15, 2024 / CoCrystal Pharma (NASDAQ:COCP), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses and noroviruses, announces that management will present a company overview at the virtual Investor Summit Microcap Forum being held Tuesday, August 20, 2024. Management will be available for 1-on-1 meetings throughout the day.

Qualified investors can register here to view the live presentation and to ask questions.

Event: Q3 Investor Summit
Date: August 20^th, 2024
Presentation Time: 9:00 a.m. ET (6:00 a.m. PT)
Location: WEBCAST LINK

• The theme is 50 micro-cap companies with a catalyst and/or strong performance in the current market.

• Take a deep dive with the best Investors in MicroCap

• Live Q & A

• Complimentary to Qualified Investors. Please REGISTER HERE.

About Cocrystal Pharma
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.

About the Investor Summit

The Investor Summit is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors. Founded in 2015.

Contact:
Fred Rockwell
fred@investorsummitgroup.com
Investor Summit Group

SOURCE: CoCrystal Pharma

View the original press release on accesswire.com

FAQ

When is CoCrystal Pharma (COCP) presenting at the Investor Summit Microcap Forum?

CoCrystal Pharma (COCP) is presenting at the Investor Summit Microcap Forum on August 20, 2024, at 9:00 a.m. ET (6:00 a.m. PT).

What is the focus of CoCrystal Pharma's (COCP) research?

CoCrystal Pharma (COCP) focuses on discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses, and noroviruses.

Can investors meet with CoCrystal Pharma's (COCP) management at the Investor Summit?

Yes, CoCrystal Pharma's (COCP) management will be available for one-on-one meetings with qualified investors throughout the day of the Investor Summit on August 20, 2024.

How can investors register for CoCrystal Pharma's (COCP) presentation at the Investor Summit?

Qualified investors can register to view CoCrystal Pharma's (COCP) live presentation and ask questions through the provided registration link in the press release.